Its values, its interview process and the questions it asks, in short episodes. Listen on a walk, then practice.
10 episodes1 free to try
No subscription needed
The final round at McKesson — typically with senior leadership — is less about your skills and more about whether you can talk substantively about the company, the industry, and your motivations. This module synthesizes everything from earlier modules into a closing strategy: how to answer "Why McKesson?" with depth, how to signal industry literacy, and how to leave the leadership round with the offer.
A working library of real behavioral questions reported by McKesson candidates on Glassdoor, Mockquestions, ClimbTheLadder, and InterviewQuery — organized by which I²CARE value each one tests. By the end you'll have a systematic mental map: when you hear the question's verb, you'll know which value to lean into and which story to pull.
McKesson runs a four-stage interview process averaging 26 days, with a 56.4% positive candidate experience rating on Glassdoor and a 2.7/5 difficulty score. This module walks through every stage — recruiter screen, technical, panel, leadership round — what to expect, how Gia (the virtual assistant) fits in, and the small-but-decisive things candidates often miss.
McKesson's history with the opioid crisis isn't ancient news — it's the central reason Integrity is the first letter in I²CARE and the central reason compliance gets weighted heavily in interviews. This module gives candidates the historical context, the compliance reforms, and the language to talk about ethics at McKesson without flinching.
Most candidates assume McKesson is a logistics company. They miss that Prescription Technology Solutions (RxTS) — anchored by CoverMyMeds — is one of the highest-margin healthcare technology platforms in the country, and it's where McKesson is investing heavily in AI and automation. This module covers what RxTS does, why it matters strategically, and what tech and product candidates need to know.
In September 2025, McKesson announced it would spin off its $11.4B Medical-Surgical Solutions business by 2027. In April 2026, Apollo Funds bought a 13% minority stake for $1.25B. These aren't routine corporate moves — they're the clearest possible signal of what kind of company McKesson is becoming. Understanding this story lets you answer "Where is the company going?" with conviction.
The U.S. Oncology Network, Sarah Cannon Research Institute, Core Ventures, and McKesson Compile aren't just business units — analysts call them McKesson's "crown jewels," and they're driving the company's margin expansion story. This module explains what each does, why they matter to McKesson's future, and how interviewers expect candidates to talk about specialty care fluently.
McKesson believes "everyone is a leader" — not just managers. The LEADRx framework (sometimes called ILEAD) defines six leadership behaviors that complement the I²CARE values. This module unpacks each behavior, explains how to demonstrate it whether you're an individual contributor or a senior leader, and shows you how to weave LEADRx language into your behavioral answers.
McKesson interviewers don't just ask behavioral questions — they map your answers onto the I²CARE framework. This module breaks down each of the six values (Integrity, Inclusion, Customer-First, Accountability, Respect, Excellence), explains what each one actually means at McKesson with real examples, and gives you a story-building framework so you walk into your interview with a tailored bank of answers.
A grounding tour of what McKesson actually does at its $300B+ scale, why it sits at the center of the U.S. healthcare supply chain, and how CEO Brian Tyler is reshaping the company around oncology, biopharma services, and prescription technology. By the end, you'll be able to explain the company's business model, segments, and recent strategic pivot in a way that signals you've done real homework.